Get the Stockscreener App
274.88
4.46%
11.74
After Hours:
274.00
-0.88
-0.32%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $274.88, with a volume of 609.56K.
It is up +4.46% in the last 24 hours and up +32.22% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$263.14
Open:
$267.06
24h Volume:
609.56K
Relative Volume:
2.67
Market Cap:
$5.51B
Revenue:
$274.48M
Net Income/Loss:
$153.56M
P/E Ratio:
37.27
EPS:
7.3755
Net Cash Flow:
$114.06M
1W Performance:
+7.98%
1M Performance:
+32.22%
6M Performance:
+38.54%
1Y Performance:
+139.78%
1-Day Range:
$265.88
$276.20
1-Week Range:
$250.37
$276.20
52-Week Range:
$110.00
$276.20
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
274.88 | 5.27B | 274.48M | 153.56M | 114.06M | 7.3755 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | BofA Securities | Buy |
| Dec-09-25 | Initiated | Citigroup | Buy |
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Ligand Pharmaceuticals director Sabba sells $544,830 in shares - Investing.com UK
Major Decision: Stephen L Sabba Exercises Options, Realizing $422K At Ligand Pharmaceuticals - Benzinga
Ligand Pharmaceuticals director Sabba sells $544,830 in shares By Investing.com - Investing.com Nigeria
Ligand Pharmaceuticals Director Sold Shares Worth Over $544K - TradingView
Ligand (NASDAQ: LGND) director exercises options and sells 2,145 common shares - Stock Titan
Ligand Pharmaceuticals stock hits 52-week high at 259.4 USD By Investing.com - Investing.com Nigeria
Ligand Pharmaceuticals Inc (LGND) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ligand Pharmaceuticals Inc (LGND) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ligand Pharmaceuticals Inc (LGND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ligand Pharmaceuticals Inc (LGND) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ligand Pharmaceuticals Inc (LGND) Institutional Confidence - TradingKey
Ligand Pharmaceuticals Inc (LGND) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ligand Pharmaceuticals Inc (LGND) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ligand Pharmaceuticals stock hits 52-week high at 259.4 USD - Investing.com India
LGND (NASDAQ) insider files Form 144 showing 1,000-share sale and June option-related sale - Stock Titan
Strategic Sale: Jason Haas Decides To Exercise Options Worth $809K At Ligand Pharmaceuticals - Benzinga
Ligand Pharmaceuticals Inc (LGND) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ligand Pharmaceuticals director Jason Haas sells $1.65m stock By Investing.com - Investing.com Nigeria
Ligand (LGND) director exercises options, sells 6,461 common shares around $255–$256 - Stock Titan
Kozarich Sells Shares of Ligand Pharmaceuticals - Intellectia AI
Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned? - Yahoo Finance
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Ligand Pharmaceuticals Stock 9-Day Winning Spree: Stock Climbs 11% - Trefis
Ligand Pharmaceuticals Stock Rockets 11% With 9-Day Winning Streak - Trefis
Insider Sell: John Lamattina Sells Shares of Ligand Pharmaceuticals Inc (LGND) - GuruFocus
Ligand Pharma director John L. LaMattina sells $1.15 million stock By Investing.com - Investing.com Canada
Ligand Pharma director John L. LaMattina sells $1.15 million stock - Investing.com
Ligand Pharmaceuticals director Jason Aryeh sells $1.25m in stock By Investing.com - Investing.com India
Ligand Pharmaceuticals director Jason Aryeh sells $1.25m in stock - Investing.com UK
Ligand Pharmaceuticals Director Sold Shares Worth Over $1.1M - TradingView
Director-linked funds trim Ligand (LGND) stake with 5,000-share sale - Stock Titan
Director sells 4,591 Ligand (LGND) shares in multiple open-market trades - Stock Titan
LGND (NASDAQ) Form 144 shows 4,000-share option exercise and restricted stock notices - Stock Titan
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date - Benzinga
JALAA Equities LP sells 500 Ligand (LGND) shares; 4,500 linked to Wells Fargo - Stock Titan
Ligand Pharmaceuticals Incorporated $LGND Shares Purchased by GW&K Investment Management LLC - MarketBeat
Franklin Resources Inc. Acquires 266,304 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals stock hits 52-week high at $254.46 By Investing.com - Investing.com Nigeria
[144] LIGAND PHARMACEUTICALS INC SEC Filing - Stock Titan
Ligand Pharmaceuticals stock hits 52-week high at $254.46 - Investing.com
Ligand Pharmaceuticals to hold Investor Day in NYC on Dec 8, 2026, sharing strategy and financial outlook. - Pluang
Ligand Announces 2026 Investor Day in New York City - The Manila Times
Los Angeles Capital Management LLC Boosts Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
BNP Paribas Financial Markets Buys 30,865 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
LGND (LGND) director receives RSUs, stock options and tax-withholding share disposition - Stock Titan
Ligand Pharmaceuticals (LGND) director awarded RSUs and options in new equity grants - Stock Titan
Director John L. Lamattina receives LGND (LGND) RSUs and stock options - Stock Titan
Ligand (LGND) director John Kozarich receives RSUs and stock options grant - Stock Titan
Ligand (NASDAQ: LGND) director Jason Haas receives RSU and option grants - Stock Titan
Ligand (LGND) director Nancy Ryan Gray receives new RSUs and options - Stock Titan
Ligand Pharma Shareholders Back Governance and Incentive Plan - TipRanks
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):